Drugs / [18F]F-RESCA-T4
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06851663 | Dec 2024 → Dec 2027 expected | cervical cancer, cholangiocarcinoma, endometrial cancer, lung cancer +6 | RenJi Hospital | Recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07026110 | Dec 2024 → Oct 2026 expected | lung cancer | RenJi Hospital | Recruiting | No outcome recorded |
| — | NCT06715839 | Dec 2024 → Sep 2027 expected | appendix cancer, bile duct carcinoma, esophageal cancer, gallbladder carcinoma +4 | RenJi Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]F-RESCA-T4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07026110 ↗ |
| Route | Other | “after \[18F\]F-RESCA-T4 injection” NCT06715839 ↗ |